Reference : Evaluation of a New Fully Automated Assay for Plasma Intact FGF23.
Scientific journals : Article
Human health sciences : Urology & nephrology
Human health sciences : Laboratory medicine & medical technology
http://hdl.handle.net/2268/218911
Evaluation of a New Fully Automated Assay for Plasma Intact FGF23.
English
Souberbielle, Jean-Claude [> >]
Prie, Dominique [> >]
Piketty, Marie-Liesse [> >]
Rothenbuhler, Anya [> >]
DELANAYE, Pierre mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie >]
Chanson, Philippe [> >]
Cavalier, Etienne mailto [Université de Liège - ULiège > Département de pharmacie > Chimie médicale >]
2017
Calcified Tissue International
101
5
510-518
Yes (verified by ORBi)
International
0171-967X
1432-0827
United States
[en] Chronic kidney disease ; FGF23 ; Hyperphosphatemia ; Hypophosphatemia ; Reference values ; Vitamin D
[en] Several FGF23 immunoassays are available. However, they are reserved for research purposes as none have been approved for clinical use. We evaluated the performances of a new automated assay for intact FGF23 on the DiaSorin Liaison platform which is approved for clinical use. We established reference values in 908 healthy French subjects aged 18-89 years, and measured iFGF23 in patients with disorders of phosphate metabolism and in patients with chronic kidney disease (CKD). Intra-assay CV was 1.04-2.86% and inter-assay CV was 4.01-6.3%. The limit of quantification was <10 ng/L. Serum iFGF23 concentrations were considerably lower than EDTA values highlighting the importance of using exclusively EDTA plasma. Liaison iFGF23 values were approximately 25% higher than Immutopics values. In the 908 healthy subjects, distribution of the Liaison iFGF23 values was Gaussian with a mean +/- 2SD interval of 22.7-93.1 ng/L. Men had a slightly higher level than women (60.3 +/- 17.6 and 55.2 +/- 17.2 ng/L, respectively). Plasma iFGF23 concentration in 11 patients with tumour-induced osteomalacia, 8 patients with X-linked hypophosphatemic rickets, 43 stage 3a, 43 stage 3b, 43 stage 4, 44 stage 5 CKD patients, and 44 dialysis patients were 217.2 +/- 144.0, 150.9 +/- 28.6, 98.5 +/- 42.0, 130.8 +/- 88.6, 130.8 +/- 88.6, 331.7 +/- 468.2, 788.8 +/- 1306.6 and 6103.9 +/- 11,178.8 ng/L, respectively. This new iFGF23 assay available on a platform that already allows the measurement of other important parameters of the mineral metabolism is a real improvement for the laboratories and clinicians/researchers involved in this field.
http://hdl.handle.net/2268/218911
10.1007/s00223-017-0307-y

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
10.1007_s00223-017-0307-y.pdfPublisher postprint515.74 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.